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Abstract: Background and Objectives: Surgical atrial fibrillation (AF) ablation concomitant to 
minimally invasive mitral valve repair has been proven to offer improved short- and long-term 
sinus rhythm (SR) maintenance compared to mitral valve surgery only. The objective of the present 
study was to explore, by thorough echocardiographic assessment, long-term morphological and 
functional left atrial (LA) outcomes after this combined surgical procedure. Materials and Methods: 
From October 2006 to November 2015, 48 patients underwent minimally invasive mitral valve 
repair and concomitant surgical AF cryoablation. Results: After 3.8 ± 2.2 years, 30 (71.4%) of those 
completing the follow-up (n = 42, 87.5%) presented SR. During follow-up, four (9.5%) patients 
suffered from cerebrovascular accidents and two of these subjects had a long-standing persistent 
AF relapse and were in AF at the time of the event, while the other two were in SR. An 
echocardiographic study focused on LA characteristics was performed in 29 patients (69.0%). Atrial 
morphology and function (e.g., maximal LA volume indexed to body surface area and total LA 
emptying fraction derived from volumes) in patients with stable SR (60.6 ± 13.1 mL/mq and 25.1 ± 
7.3%) were significantly better than in those with AF relapses (76.8 ± 16.2 mL/mq and 17.5 ± 7.4%; 
respectively, p = 0.008 and p = 0.015). At follow-up, patients who suffered from ischemic cerebral 
events had maximal LA volume indexed to body surface area 61 ± 17.8 mL/mq, with total LA 
emptying fraction derived from volumes 23.6 ± 13.7%; patients with strokes in SR showed very 
enlarged LA volume (>70 mL/mq). Conclusions: AF cryoablation concomitant with minimally 
invasive mitral valve repair provides a high rate of SR maintenance and this relates to improved 
long-term morphological and functional LA outcomes. Further prospective studies are needed to 
define the cut-off values determining an increase in the risk for thromboembolic complications in 
patients with restored stable SR. 
Keywords: atrial fibrillation; surgical cryoablation; left atrial function; minimally invasive mitral 
valve repair; echocardiography; ischemic cerebral events 
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1. Introduction 
Atrial fibrillation (AF) prevalence in patients with indication for mitral valve surgery is about 
30–54% [1], it has a strong impact on hemodynamics [2], and it has been demonstrated to 
significantly affect the mortality rate [3,4]. 
Concomitant surgical AF ablation to video-assisted minimally invasive mitral valve surgery 
(MIMVS) [5–7] has been proven to offer improved short- and long-term sinus rhythm (SR) 
maintenance compared to patients undergoing mitral valve surgery only (73% versus 43% of SR 
maintenance at 12 months’ follow-up) [8] without increasing complications [9,10]. 
Therefore, SR maintenance seems achievable, but does this reflect in an improved atrial function? It 
has been demonstrated that SR maintenance is related to reduced left atrial volumes [11], but little is 
known about left atrial (LA) functional properties in this clinical setting. In fact, an organized atrial 
activity is not always accompanied by an effective mechanical atrial contraction [12]. 
In patients with underlying mitral valve diseases, atrial remodeling is remarkable: 
longstanding volume overload to the LA results in chronic stretching and atrophy of atrial 
myocytes, interstitial fibrosis, overall thinning, and dilatation of the LA wall, which may relate to 
functional alterations despite the underling electrical activity. 
To date, however, it remains unknown to which degree “the residual atrial function” after a 
successful AF ablation predicts clinical outcome. For example, which level of contractility is required 
to avoid the increased thromboembolic risk of a “static” LA, despite SR? 
The aim of the present study was therefore to describe, by a thorough echocardiographic 
assessment, long term LA morphology and function in patients submitted to surgical ablation of 
persistent/long-term persistent AF concomitant to MIMVS. 
2. Materials and Methods 
2.1. Surgical Procedure 
According to current guidelines, patients referred to our Cardiac Surgery Division for mitral 
valve disease and AF resistant to antiarrhythmic therapy, when technically feasible, were proposed 
video-assisted MIMVS via right mini-thoracotomy through the fourth intercostal space and 
concomitant left sided AF cryoablation. All enrolled patients were retrospectively identified, starting 
since October 2006. Patients that had already performed a cardiac surgical procedure or a previous 
transcatheter AF ablation were not included in this series. Each patient in our study signed a written 
informed consent for inclusion. The study was conducted in accordance with the Declaration of 
Helsinki, was observational and retrospective, did not add treatment or modify conventional 
surgical procedure for the specific clinical indication and was approved by the local Institutional 
Review Board (Project Identification “CryoMIMS—Concomitant Cryoablation to Video-assisted 
Minimally INvasive Mitral Valve Surgery”, code 9718; date of approval 1 February 2016). 
Surgical technique has already been described [13]. 
Concomitant left sided AF cryoablation (Argon based Cryomaze, Cryoflex Medtronic, 
Minneapolis, MN, USA) consisted of isolation of the pulmonary veins (PVs) and of the posterior LA 
wall between the veins by a “U” encircling cryolesion connected to the surgical paraseptal LA 
incision performed for mitral exposure, eventually creating the so-called “box lesion”. In addition, a 
linear cryolesion was performed from the previously created box lesion to the mitral valve annulus 
to block conduction across the left atrial isthmus (“mitral line”) [6,14]. The surgical procedure 
performed was the same in every patient included in the study. 
2.2. Echocardiographic Analysis 
Complete echocardiographic assessment was performed in patients undergoing mitral valve 
repair by the MIMVS approach and concomitant left sided AF cryoablation. The echocardiographic 
assessment was performed at 4.0 ± 2.1 years after the surgical procedure. Subjects who underwent 
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mitral valve replacement with biological or mechanical prosthesis were excluded due to distortions 
related to the presence of the prosthetic scaffold. 
Echocardiographic scans were performed by a Philips ultrasound system (iE33 xMATRIX, 
Andover, MA, USA) with S5-1 sector array probe and X3-1 3D probe. All the examinations were 
carried out by the same operator. Standard measurements were computed based on the American 
Society of Echocardiography guidelines. Maximum left atrial diameter (LAD max), minimum (LAD 
min) and at the beginning of atrial contraction (LAD pre-A) antero-posterior diameters were measured 
in the parasternal long axis view by either B-mode or M-mode technique (Figure 1A). 
The apical four chamber view was used to measure maximum left atrial supero-inferior 
diameter (Figure 1B). 
 
Figure 1. Echocardiographic evaluation of left atrial function: (A) measurement of antero-posterior 
diameters; (B) evaluations of areas and volumes and measurement of maximum supero-inferior 
diameter; (C) measurement of transmitral peak velocity of the late filling wave (A wave); (D) 
measurement of lateral mitral annulus peak velocity related to atrial contraction (a’ wave) and 
evaluation of atrial conduction delay; (E) calculation of maximum 3D volume; (F) evaluation of 
global longitudinal atrial strain. 
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The left atrial volumes were evaluated by modified Simpson’s method using the apical four 
chamber view at the tele-systolic frame preceding the mitral valve opening (maximum volume, LAV 
max), at the tele-diastolic frame preceding mitral valve closure (minimum volume, LAV min), and at 
the beginning of the P wave for the subjects not in AF at the moment of the exam (pre A volume, 
LAV pre-A) (Figure 1B). 
Volumes were subsequently indexed on the body surface area. 
From the above-mentioned linear measurements and volumes, the following parameters 
defining different components of LA function were calculated: 
• Left atrial active emptying fraction, related to the LA booster pump function; 
• Left atrial passive emptying fraction, describing the LA conduit function; 
• Left atrial total emptying fraction, defining the LA reservoir function. 
Similarly, the LA areas (maximal, minimal, and at the beginning of the P wave) were measured 
(Figure 1B). The LA ejection fraction was calculated from maximal and minimal areas, being reduced 
if ≤45% [15]. 
Left atrial 3D maximum volume was calculated using the QLAB-3D Quantification (3DQ) 
Advanced application (Figure 1E). 
The transmitral flow velocity was measured by pulsed Doppler echocardiography. Peak velocity of 
the early filling wave (E wave) and of the late filling wave (A wave) were determined (Figure 1C), 
considering a peak A wave velocity ≥10 cm/s an indicator of the presence of some atrial contraction [16]. 
The lateral and septal mitral annulus peak velocities related to early relaxation (e’ wave) and to 
atrial contraction (a’ wave) were evaluated by tissue Doppler imaging (TDI, Figure 1D). A TDI a’ ≤7 
cm/s was considered an index of anomalous LA active contractile function [17]. 
Furthermore, atrial conduction time was measured: the PA-TDI interval was calculated, 
defined as the time interval between the beginning of the P wave and the TDI a’ wave (Figure 1D). 
The standard deviation of PA-TDI measurements performed on all segments was also calculated for 
every single patient. 
Eventually, LA global longitudinal strain by two-dimensional speckle tracking was calculated 
for every patient by QLAB CMQ Cardiac Motion Quantification (Figure 1F). 
2.3. Clinical Follow-Up and Event Definition 
After discharge patients were followed by outpatient visits, including clinical examinations and 
ECG at 3, 6, and 12 months and then yearly. At least once a year, 24 h ECG Holter monitoring was 
performed. In case of symptoms recurrence between follow-up visits, patients were reassessed by 
clinical examination, ECG, and Holter monitoring. Electrophysiological study and transcatheter AF 
ablation were performed when indicated. All patients in the study were followed for at least six months. 
A blanking period of three months was considered; following this interval any AF episode, 
persistent or paroxysmal, was accounted as an event. 
2.4. Statistical Analysis 
Categorical variables are reported as counts and percentages, while continuous variables as 
means and standard deviations (SDs). Correlations between parameters and study groups were 
tested in cross tabulation tables by means of the Pearson Chi-Square or Fisher’s exact test and by 
one-way ANOVA, respectively, for categorical and continuous variables. McNemar’s test was used 
on paired categorical variables. Kaplan Meier curves were computed to describe AF free survival 
over time. A two-sided p-value < 0.05 was considered statistically significant; all analyses were 
performed on SPSS 20.0 (IBM Corp., Armonk, NY, USA). 
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3. Results 
From October 2006 to November 2015, 48 patients were submitted to minimally invasive mitral 
valve repair and concomitant AF cryoablation. The baseline characteristics of the study population 
are listed in Table 1. 
Table 1. Preoperative characteristics of the study population stratified by AF relapses at follow-up. 
(AF, atrial fibrillation; AP, antero-posterior; BMI, body mass index; BSA, body surface area; COPD, 
chronic obstructive pulmonary disease; LS, long-standing; MV, mitral valve; NYHA, New York 
Heart Association functional class; PAPs, systolic pulmonary artery pressure; SI, supero-inferior; SR, 
sinus rhythm; TV, tricuspid valve). 
 N = 48 
AF Relapse  
(N = 12/42 28.6%)
SR Maintenance 
(N = 30/42 71.4%) 
p-Value
Age (years) 67.7 ± 9.8 69.0 ± 6.9 66.7 ± 11.3 0.516 
Male gender (N,%) 31 (64.6%) 5 (41.7%) 20 (66.7%) 0.127 
NYHA class ≥III (N,%) 31 (64.6%) 10 (83.3%) 17 (56.7%) 0.054 
BSA (mq) 1.8 ± 0.19 1.78 ± 0.21 1.82 ± 0.19 0.502 
Obesity (BMI > 30) (N,%) 14 (29.2%) 4 (33.3%) 9 (30.0%) 0.619 
COPD (N,%) 8 (16.7%) 2 (16.7%) 5 (16.7%) 0.615 
Hypertension (N,%) 32 (66.7%) 9 (75.0%) 21 (70.0%) 0.496 
Diabetes (N,%) 5 (10.4%) 1 (8.3%) 4 (13.3%) 0.488 
Dysthyroidism (N,%) 11 (22.9%) 2 (16.7%) 9 (30.0%) 0.231 
Previous cerebrovascular accidents (N,%) 5 (10.4%) 1 (8.3%) 4 (13.3%) 0.488 
CHADS2 score  2.29 ± 1.17 2.12 ± 0.93 2.33 ± 1.27 0.542 
CHA2DS2VASc score 3.41 ± 1.52 3.47 ± 1.28 3.37 ± 1.63 0.825 
Antiarrhythmic therapy at the time of surgery (N,%) 17 (35.4%) 5 (41.7%) 12 (40.0%) 0.473 
Type of AF   
0.001 Paroxysmal (N,%) 7 (14.6%) 0 (0.0%) 7 (23.3%) 
Persitent/LS persistent (N%) 40 (83.3%) 12 (100%) 22 (73.3%) 
AF duration (days) 1077.6 ± 2052.4 1347.9 ± 2406.3 550.4 ± 849.9 0.127 
Left ventricular ejection fraction (%) 57.1 ± 10.5 57.5 ± 10.1 57.6 ± 11.0 0.984 
Etiology of MV disease  
0.289 
Degenerative 32 (66.7%) 7 (58.3%) 22 (73.3%) 
Rheumatic 1 (2.1%) 1 (8.3%) 0 (0.0%) 
Functional 13 (27.1%) 4 (33.3%) 6 (20.0%) 
Left atrial AP diameter (mm) 50.9 ± 10.0 51.1 ± 7.0 51.8 ± 12.1 0.899 
Left atrial SI diameter (mm) 65.5 ± 9.1 68.3 ± 10.4 66.6 ± 8.1 0.754 
PAPs (mmHg) 43.2 ± 14.1 42.9 ± 12.0 44.1 ± 15.8 0.822 
Twenty (41.7%) patients underwent simple valve repair while 28 (58.3%) were submitted to 
complex valve repair. Seven subjects (14.6%) received concomitant tricuspid valve surgery. Only one 
procedure was electively converted to full sternotomy (2.1%) due to unexpected severe pleural 
adhesions. Total clamp time was 99.5 ± 25.6 min. There was no reopening for any cause. 
About one third of the study population (18, 37.5%) suffered AF relapses during 
hospitalization, while 39 (81.3%) patients were discharged in SR. One patient (2.1%) required PM 
implantation in the subacute phase. Early mortality was 2.1% (one patient died due to respiratory 
complications following cardiac arrest resuscitated in the ward). 
By April 2016, 42 (87.5%) patients completed the follow-up after a mean of 3.8 ± 2.2 years from 
the procedure. The study flow chart is depicted in Figure 2. 
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Figure 2. Study flow chart. AF: atrial fibrillation; EP: electrophysiological; SR: sinus rhythm. 
Except the patient who died few days after surgery, the remaining four deaths were not due to 
cardiovascular causes. 
In this time frame no patient required redo surgery. 
NYHA functional class showed a significant improvement (NYHA ≥ 3 patients decreased from 
64.6% pre-surgery to 4.8% at follow-up, p < 0.001). Three (7.1%) patients required PM implantation 
during follow-up. 
Thirty patients (71.4%) maintained SR throughout the follow-up. Out of the 12 (28.6%) patients 
suffering AF relapses, three (25%) had paroxysmal episodes, while nine (75%) developed persistent 
AF (Figure 2). Five (41.7%) patients relapsed with an atypical atrial flutter, while the remaining 
seven (58.3%) as AF. Out of all patients, one patient (8.3%) suffered symptomatic recurrences and 
was referred for electrophysiological study and transcatheter redo ablation. Following transcatheter 
ablation he relapsed with an asymptomatic focal atrial tachycardia. A total of 16 (38%) patients were 
on antiarrhythmic therapy at follow-up; this percentage did not significantly vary between patients 
maintaining SR (10, 33%) or suffering AF relapses (6, 50%; p = 0.315). Oral anticoagulation was 
discontinued, instead, in 16 patients (53%) maintaining stable SR at the follow-up end, whereas it 
was continued in all the patients with documentation of AF relapses. 
Freedom from arrhythmias is reported in Figure 3, showing a 91.7% one-year freedom from AF 
relapses. 
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Figure 3. Kaplan Meier curves for freedom from AF relapses. 
During follow-up, four (9.5%) patients suffered from cerebrovascular accidents; two of these 
subjects had a long-standing persistent AF relapse and were in AF at the time of the event, while the 
other two were in SR. 
Thorough LA morphology and function was assessed at follow-up within 29 patients (69.0%) 
treated by mitral repair; out of the other 19 patients submitted to mitral valve repair who did not 
undergo the LA focused echocardiographic evaluation, one (2.1%) was converted to full sternotomy, 
five (10.4%) died (two of cancer, two of other non-cardiac causes, and only one due to respiratory 
complications following cardiac arrest), and the remaining 13 patients (27.1%) were contacted only 
by telephone or fax, owing to problems of access due to long distances between the medical center 
and the patients’ residences, being our hospital a reference center for surgery. 
Among the 29 patients, four (13.8%) had paroxysmal AF, whereas 25 (86.2%) had 
persistent/long-standing persistent AF at baseline. 
In this subset, 22 patients (75.9%) presented a good outcome of mitral repair with a residual 
mitral regurgitation absent or trivial in 15 subjects (68.2%) and mild in seven (31.8%). 
At the moment of the echocardiographic scan, 22 subjects (75.9%) were in SR, while six (20.7%) 
were in atrial fibrillation/atypical atrial flutter, and one (3.4%) presented an atrial paced rhythm. At 
univariate analysis the residual mitral regurgitation did not relate to AF relapses (p = 0.103). 
Table 2 shows details concerning all measurements and functional parameters stratified by 
heart rhythm at the time of the echo scan. Patients suffering relapses reported more enlarged left 
atria and more significantly impaired LA function. 
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Table 2. Echocardiographic parameters and atrial functional evaluations, expressed as mean of the 
total population and stratified on the basis of presenting rhythm during echocardiography. (AF, 
atrial fibrillation; AP, antero-posterior; BSA, body surface area; DT, deceleration time; EF, ejection 
fraction; LA, left atrial; LV, left ventricular; PAPs, systolic pulmonary arterial pressure; RA, right 
atrial; SI, supero-inferior; SR, sinus rhythm). 
 N = 29 SR (N = 22/29) AF (N = 6/29) p-Value 
Max LA AP diameter (mm)  53.4 ± 6.7 51.5 ± 5.9 59.8 ± 6.0 0.018 
Min LA AP diameter (mm) 46.7 ± 7.2 44.4 ± 6.0 55.0 ± 5.1 0.002 
Total LA emptying fraction derived from 
AP diameters (%) 
12.7 ± 4.4 14.1 ± 4.1 8.0 ± 1.6 0.006 
Max LA SI diameter (mm) 68.3 ± 5.4 67.2 ± 4.6 74.0 ± 3.7 0.003 
Max LA area (cmq) 31.8 ± 5.2 30.4 ± 4.3 37.3 ± 5.5 0.010 
Min LA area (cmq) 27.0 ± 5.1 25.3 ± 3.8 33.4 ± 4.8 0.001 
LA ejection fraction derived from areas (%) 15.5 ± 5.4 16.7 ± 5.3 10.5 ± 2.8 0.028 
Max LA volume (mL) 120.4 ± 32.6 111.5 ± 25.9 152.8 ± 39.0 0.016 
Max LA volume/BSA (mL/mq) 65.6 ± 15.8 60.9 ± 12.5 80.7 ± 18.2 0.010 
Min LA volume (mL) 93.5 ± 28.7 84.4 ± 21.1 127.7 ± 30.9 0.002 
Min LA volume/BSA (mL/mq) 60.0 ± 14.5 46.2 ± 11.2 67.5 ± 14.4 0.002 
3D LA volume (mL) 111.6 ± 38.2 100.2 ± 25.5 158.1 ± 51.7 0.005 
3D LA volume/BSA (mL/mq) 61.1 ± 18.9 54.9 ± 12.4 84.0 ± 24.9 0.003 
Total LA emptying fraction derived from 
volumes (%) 
22.7 ± 8.0 24.4 ± 7.9 16.0 ± 5.7 0.061 
Global longitudinal LA strain (%) 8.5 ± 3.8 9.7 ± 3.6 5.2 ± 1.7 0.013 
E wave (cm/s) 137.2 ± 23.7 136.4 ± 25.8 143.5 ± 14.4 0.552 
A wave (cm/s) 56.2 ± 19.8 57.1 ± 19.8  0.286 
Inferior septal a’ wave (cm/s) 5.8 ± 2.0 5.9 ± 2.0  0.508 
Lateral a’ wave (cm/s) 4.5 ± 1.6 4.6 ± 1.6  0.356 
Averaged a’ wave (cm/s) 5.2 ± 1.5 5.2 ± 1.5  0.352 
P-lateral a’ wave interval (ms) 110.6 ± 31.9 110.3 ± 32.7  0.866 
LV EF (%) 57.3 ± 8.0 57.9 ± 6.8 53.8 ± 11.7 0.352 
PAPs (mmHg) 37.7 ± 9.4 37.0 ± 9.6 38.2 ± 9.4 0.479 
Similar trends emerged, as shown in Table 3, if measurements and functional parameters were 
stratified by heart rhythm during follow-up: 20 (69.0%) SR and nine (31.0%) AF recurrences. 
Table 3. Echocardiographic parameters and atrial functional evaluations, stratified according to SR 
maintenance and type of AF recurrence during follow-up. (AF, atrial fibrillation; AP, 
antero-posterior; BSA, body surface area; DT, deceleration time; EF, ejection fraction; LA, left atrial; 
LS, long-standing; LV, left ventricular; PAPs, systolic pulmonary arterial pressure; RA, right atrial; 
SD, standard deviation; SI, supero-inferior; SR, sinus rhythm). 
 
Stable SR 
(N = 
20/29) 
AF Relapse 
(N = 9/29) 
Paroxysmal AF 
Relapse (N = 
3/29) 
Persistent/LS 
Persistent AF Relapse 
(N = 6/29) 
p-Value 
Max LA AP diameter 
(mm)  
51.4 ± 6.2 57.8 ± 5.9 53.7 ± 3.2 59.8 ± 6.0 0.019 
Min LA AP diameter 
(mm) 
44.3 ± 6.3 52.2 ± 6.0 46.7 ± 3.2 55.0 ± 5.1 0.002 
P wave LA AP diameter 
(mm) 
47.5 ± 6.1  49.7 ± 4.2  0.565 
Active LA emptying 
fraction derived from AP 
diameters (%) 
7.0 ± 3.2  5.9 ± 3.0  0.601 
Passive LA emptying 
fraction derived from AP 
diameters (%) 
7.7 ± 3.4  7.5 ± 2.3  0.945 
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Total LA emptying 
fraction derived from AP 
diameters (%) 
14.1 ± 4.2 9.7 ± 3.0 13.1 ± 1.9 8.0 ± 1.6 0.006 
Max LA SI diameter (mm) 67.0 ± 4.9 71.4 ± 5.2 66.3 ± 4.0 74.0 ± 3.7 0.009 
Max LA area (cmq) 30.1 ± 4.3 35.6 ± 5.3 32.2 ± 3.1 37.3 ± 5.5 0.007 
Min LA area (cmq) 24.9 ± 3.8 31.4 ± 4.9 27.5 ± 2.2 33.4 ± 4.8 <0.001 
P wave LA area (cmq) 27.0 ± 4.0  28.9 ± 2.2  0.430 
LA ejection fraction 
derived from areas (%) 
17.2 ± 5.0 11.8 ± 4.6 14.3 ± 7.2 10.5 ± 2.8 0.022 
Max LA volume (mL) 
109.9 ± 
26.4 
143.8 ± 34.4 125.7 ± 13.6 152.8 ± 39.0 0.012 
Max LA volume/BSA 
(mL/mq) 
60.6 ± 13.1 76.8 ± 16.2 69.0 ± 9.1 80.7 ± 18.2 0.016 
Min LA volume (mL) 82.4 ± 21.0 118.2 ± 28.7 99.3 ± 10.2 127.7 ± 30.9 0.001 
Min LA volume/BSA 
(mL/mq) 
45.4 ± 10.9 63.3 ± 14.2 55.0 ± 11.6 67.5 ± 14.4 0.002 
P wave LA volume (mL) 92.9 ± 22.7  104.3 ± 8.1  0.402 
P wave LA volume/BSA 
(mL/mq) 
51.3 ± 11.6  57.6 ± 10.4  0.380 
3D LA volume (mL) 
101.6 ± 
26.6 
134.0 ± 51.6 93.9 ± 11.2 158.1 ± 51.7 0.005 
3D LA volume/BSA 
(mL/mq) 
56.2 ± 13.2 71.9 ± 25.6 51.7 ± 8.4 84.0 ± 24.9 0.005 
Active LA emptying 
fraction derived from 
volumes (%) 
11.4 ± 5.4  4.9 ± 3.0  0.057 
Passive LA emptying 
fraction derived from 
volumes (%) 
15.5 ± 6.3  16.5 ± 9.0  0.809 
Total LA emptying 
fraction derived from 
volumes (%) 
25.1 ± 7.3 17.5 ± 7.4 20.4 ± 10.9 16.0 ± 5.7 0.039 
Global longitudinal LA 
strain (%) 
9.8 ± 3.8 5.8 ± 1.9 7.0 ± 2.0 5.2 ± 1.7 0.021 
E wave (cm/s) 
131.4 ± 
24.2 
150.0 ± 17.6 163.0 ± 18.2 143.5 ± 14.4 0.070 
A wave (cm/s) 54.7 ± 20.0  66.1 ± 19.5  0.364 
Inferior septal a’ wave 
(cm/s) 
6.0 ± 2.0  4.9 ± 2.2  0.409 
Lateral a’ wave (cm/s) 4.6 ± 1.7  3.6 ± 0.8  0.306 
Averaged a’ wave (cm/s) 5.3 ± 1.5  4.3 ± 1.5  0.274 
P-lateral a’ wave interval 
(ms) 
110.8 ± 
28.9 
 109.0 ± 57.3  0.930 
SD P-a’ wave intervals 0.56 ± 0.31  0.63 ± 0.47  0.736 
LV EF (%) 58.0 ± 7.2 55.8 ± 9.8 59.7 ± 3.5 53.8 ± 11.7 0.484 
PAPs (mmHg) 36.2 ± 9.3 40.7 ± 9.5 45.7 ± 9.0 38.2 ± 9.4 0.284 
Table 3 points out the markedly enlarged dimensions of the LA, compared to healthy subjects 
[18], also in patients who maintained SR during the follow-up: the maximum anteroposterior 
diameter was 51.4 ± 6.2 mm (versus normal values of <41 mm); the maximum indexed volume 60.6 ± 
13.1 mL/mq (versus normal values of 22 ± 6 mL/mq); the minimum indexed volume 45.4 ± 10.9 
mL/mq (versus normal values of 11 ± 4 mL/mq); the preA indexed volume 51.3 ± 11.6 mL/mq (versus 
normal values of 15 ± 5 mL/mq); the maximum indexed 3D volume 56.2 ± 13.2 mL/mq (versus 
normal values of 15–41 mL/mq). However, these same parameter results significantly increased in 
patients suffering AF relapses at follow-up. 
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Similarly, SR patients showed a reduction in atrial function when compared to normal values of 
healthy controls (transmitral A wave velocity 54.7 ± 20.0 cm/s versus 80 ± 20 cm/s [19]; TDI lateral a’ 
wave 4.6 ± 1.7 cm/s, septal a’ wave 6.0 ± 2.0 cm/s, averaged a’ wave 5.3 ± 1.5 cm/s versus values >7.3 
cm/s [17]; LA ejection fraction by areas 17.2 ± 5.0% versus 45% [15]; total emptying fraction by 
volumes 25.1 ± 7.3% versus normal values ranging from 45% to 65 ± 9% [18,20,21]; active and passive 
emptying fractions by volumes 11.4 ± 5.4% and 15.5 ± 6.3% versus 46.6 ± 11.7% and 44.3 ± 12.1% [22], 
respectively; global strain 9.8 ± 3.8% versus 22.9 ± 11.7% [23]). All these parameters, however, were 
less severely depressed compared to patients with arrhythmia relapses. 
At follow-up, patients who suffered from ischemic cerebral events had maximal LA volume/BSA 61 
± 17.8 mL/mq, minimum LA volume/BSA 45.4 ± 5.2 mL/mq, total LA emptying fraction derived from 
volumes 23.6 ± 13.7%, lateral a’ wave 4.3 ± 0.2 cm/s, and SD of PA-TDI measurements 0.45 ± 0.08. The two 
patients with strokes in SR showed, instead, extremely enlarged LA volume (>70 mL/mq). One patient 
suffering a cerebrovascular event despite SR had discontinued oral anticoagulation therapy. The other 
three patients were on anticoagulation therapy at the time of stroke. 
4. Discussion 
It is reasonable to infer that a lack of recovery of an efficient mechanical atrial activity, even 
potentially in the presence of SR, facilitates intra-atrial thrombus formation and subsequent systemic 
thromboembolic phenomena. 
Previous studies on surgical AF ablation concomitant to valve surgery reported a highly 
variable incidence, from 21% to 87%, of both SR restoration and atrial contraction recovery [24,25]. 
Following the classic LA Maze ablation, it has already been proven that, despite successful SR 
restoration, there is a progressive loss of LA function, especially within patients affected by 
rheumatic mitral disease [26]. 
Following the latest less extensive LA ablation protocols, sparing large areas of the LA, instead, 
data are controversial. On one side, Loardi et al. analyzed 122 patients: based on transmitral peak A 
velocity as an atrial contraction index, they proved that 76% of the subjects presented SR and a 
normal atrial function at three months, and this percentage even increased to 98% after two years 
[27]. Similarly, Reyes et al. [28], out of 33 patients, highlighted the presence of a transmitral flow in 
70% of SR patients at six months follow-up. Analogous results were reported by Manasse et al. [29]. 
On the other side, in patients with stable SR at six months follow-up, Johansson et al. [30] 
demonstrated a significant reduction in transmitral A wave velocity in 15 subjects submitted to 
combined surgery procedure as compared with 14 subjects submitted to mitral valve surgery alone. 
Boyd et al. suggested that the ablation procedure might have been responsible for the atrial 
dysfunction observed [31]. In addition, Schiros et al., comparing 35 degenerative mitral 
regurgitation patients undergoing combined surgery to 51 normal controls by means of cardiac 
magnetic resonance imaging, asserted that LA volumes and function do not return to normal values 
at one year distance (in particular, total atrial emptying fraction derived from volumes resulted in 
45% pre-operative and 42% at one year post-surgery, versus 54% in controls) [32] supporting the 
relevant role of the underlying intrinsic disease of the atrial myocardium. Similar results were also 
reported by Kim et al. [33] within 12 patients: at one month follow-up the LA emptying fraction at 
computed tomography was 16.8 ± 6.3% (significantly lower than in controls, 47.9 ± 11.2%, p < 0.001) 
despite SR, and atrial contractile function did not improve over the following six months. 
Lastly, Compier et al. placed emphasis on the fact that, notwithstanding the limited lesion set 
during concomitant cardiac surgery, LA compliance, transport function and contraction, decreased 
after ablation, were not restored in approximately half of the patients with post-procedural SR [34]. 
The present study highlights the markedly enlarged dimensions and reduced LA function also 
in patients who maintained SR during the entire follow-up period, compared to data reported in the 
literature for healthy subjects (see Results section). However, these parameters are more severely 
depressed, compared to healthy subjects, when patients suffer arrhythmia relapses (Table 3). These 
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results support that concomitant AF cryoablation, by SR maintenance, guarantees an advantage, 
even if in the setting of deteriorated LAs, in terms of reverse remodeling. 
Similar results were found in the HESTER (Has Electrical Sinus Translated into Effective 
Remodelling?) study [35]: in this experience, adjunct surgical maze was associated with the recovery of 
LA function but with a mean active LA ejection fraction (ALAEF) lower in maze patients than in control 
subjects. Providing evidence that function is restored after adjunct maze, potential clinical benefits in 
reducing thromboembolic and heart failure risk will arise. Determining whether patients can safely stop 
taking anticoagulants after SR is restored by a maze procedure requires, instead, longer term follow-up 
and stroke surveillance, beyond those of the HESTER study. In any case, the varying rates of LA 
functional recovery after maze strongly suggest that, at least, it would be judicious to measure LA 
function before considering anticoagulation withdrawal. 
As stated in a previous study of our group [12] we suggest that, at least within patients with 
severely enlarged left atrium, previous cardiac surgery and catheter or surgical AF ablation, especially if 
repeated, the assessment of atrial contractility by transthoracic echocardiography should be performed 
before discontinuing oral anticoagulants (OAC), also in patients who maintain SR, despite confirmation 
by serial ECG or Holter monitorings. In our opinion, SR and LA contractility recovery represent two 
sides of the same coin, and both should be weighted carefully with the objective of selecting patients 
who could benefit from OAC continuation/discontinuation following an AF ablation. 
There is a real need for improvement in patient stratification and personalization of care after 
AF ablation. Our understanding of which patients should continue anticoagulants for stroke 
prevention needs to be further refined to reduce the number of patients receiving anticoagulation 
after a successful AF ablation, and consequently lower the number of hemorrhagic complications, 
while endorsing the continuation of OAC in patients with a higher risk profile, and prevent 
thromboembolic events. In this context, we believe echocardiographic assessment of the restoration 
of an efficient LA contractility should be included among decisional criteria. 
Further prospective studies are needed to define the LA dimensions and function cut-off values 
determining an increase in the risk for thromboembolic complications in patients with restored stable SR. 
Moreover, quantitative assessment of LA function may have clinical utility in guiding early surgical 
intervention and concomitant ablation in patients with mitral regurgitation and AF [36,37]. 
4.1. Study Limitations 
This report is an observational and retrospective study. The limited sample size may have 
influenced the statistical power of the analysis. A comparison with baseline echocardiographic data 
is not completely feasible because a detailed echocardiography focused on LA morphology and 
function was not routinely performed before surgery. In addition, echocardiographic follow-up data 
were not available for the entire cohort of patients. Despite this limitation, we believe our data are 
representative and of interest. In fact, despite patients lost to follow-up, echocardiographic 
parameters concerning atrial function in patients followed and with stable SR, after the combined 
surgical procedure, proved statistically better than in subjects with AF relapse. Being aware that 
arrhythmia monitoring based on serial 24 h ECG Holter tracings or, even better, implantable 
recorders would be more accurate, in a mostly persistent AF setting, consideration of any AF 
relapse, also those present only once during the follow up, should limit event underestimation. 
The present study is a starting point; in any case, we are convinced that the concept introduced 
by the present manuscript may have wider developments in clinical practice. 
5. Conclusions 
Surgical AF cryoablation concomitant to minimally invasive mitral valve repair was determined to 
be highly effective in maintaining SR and reducing AF burden at long-term follow-up. 
The present study highlights the markedly enlarged dimensions of the LA also in patients who 
maintained SR during the entire follow-up period. 
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However, at the echocardiographic evaluation, data concerning atrial function in patients with 
stable SR after the combined surgical procedure are significantly better than in subjects with AF relapse 
at follow-up. This finding supports the implementation of AF cryoablation concomitant to MIMVS. 
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